On September 20, the High Authority for Health gave the green light to three anti-Covid vaccines adapted to Omicron for a new booster vaccination campaign planned for the fall and coupled with that against the flu.
In a press release published on September 20, the High Authority for Health (HAS) announced that it authorized three vaccines adapted to the variant of Covid-19, Omicron. A new booster dose for this fall will be recommended for people at risk of severe form, their entourage and caregivers.
The HAS recommends “indifferently one of the three bivalent vaccines” – two developed by Pfizer/BioNTech, the third by Moderna – recently validated by the European Medicines Agency.
“Based on the available data and in an epidemic context marked by the majority circulation of the BA.5 sub-variant”, the HAS recommends using “preferably” one of these vaccines, all with messenger RNA, for a new fall booster dose. This recommendation applies regardless of the anti-Covid vaccine initially administered to the person.
“Like seasonal influenza vaccines, updated each year to take into account the viruses that are most likely to circulate during the winter, bivalent mRNA vaccines are not new vaccines but vaccines adapted to the strains circulating”, underlines the HAS in its writing.
These are the vaccines from Moderna and Pfizer/BioNTech targeting the original strain of the virus and the BA.1 variant of Omicron, and the vaccine from Pfizer/BioNTech targeting the original strain and the BA subvariants .4 and BA.5 from Omicron.
An anti-flu campaign will start on October 18
The HAS is also maintaining its recommendation to combine the booster vaccination campaign against Covid-19 with that of vaccination against influenza, which will start on October 18. A concomitant injection or the same day of the two vaccines is possible, she recalls.
“In the immediate term and because the number of cases of infections has started to rise again for a few days”, this health authority recommends not to postpone the second booster dose in people over 60 and under 60. at risk of a severe form who have not received it within the recommended time frame.
It recalls the effectiveness of current vaccines (monovalent) against severe forms of Covid-19.
RT All Fr Trans